310 related articles for article (PubMed ID: 16109123)
1. A pilot study of botulinum toxin A for headache in cervical dystonia.
Ondo WG; Gollomp S; Galvez-Jimenez N
Headache; 2005 Sep; 45(8):1073-7. PubMed ID: 16109123
[TBL] [Abstract][Full Text] [Related]
2. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
3. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
7. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
11. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
12. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Dowson AJ; Kilminster SG; Salt R
Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
[TBL] [Abstract][Full Text] [Related]
13. Headache attributed to craniocervical dystonia: A prospective cohort study.
Eugenio Ramalho Bezerra M; Sampaio Rocha-Filho PA
Eur J Pain; 2020 Sep; 24(8):1484-1494. PubMed ID: 32422691
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
15. [Influence of botulinum toxin treatment on previous primary headaches in patients with cranio-cervical dystonia].
Pascual J
Neurologia; 2004 Jun; 19(5):260-3. PubMed ID: 15150709
[TBL] [Abstract][Full Text] [Related]
16. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.
Cano SJ; Hobart JC; Edwards M; Fitzpatrick R; Bhatia K; Thompson AJ; Warner TT
Neurology; 2006 Dec; 67(12):2230-2. PubMed ID: 17190951
[TBL] [Abstract][Full Text] [Related]
17. Headache in cranial and cervical dystonia.
Barbanti P; Fabbrini G; Pauletti C; Defazio G; Cruccu G; Berardelli A
Neurology; 2005 Apr; 64(7):1308-9. PubMed ID: 15824376
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
Tarsy D
Mov Disord; 1997 Jan; 12(1):100-2. PubMed ID: 8990061
[TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases.
Tepper SJ; Bigal ME; Sheftell FD; Rapoport AM
Headache; 2004 Sep; 44(8):794-800. PubMed ID: 15330826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
